Regeneron to stop enrolling very sick Covid-19 patients in antibody trials
Regeneron Pharmaceuticals will stop enrolling patients receiving advanced Covid-19 care in a trial testing the company’s experimental antibody treatment in hospitalized patients, based on the recommendation of an independent safety board.